Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 11/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 11/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618922 | 0.68 | CHRM5 (0.37) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL745221 | 0.66 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356574 | 0.66 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL20795047 | 0.66 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6952194 | 0.66 | KDM4E (0.36) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL745115 | 0.65 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1902519 | 0.65 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL1489507 | 0.64 | CHRM2 (0.30) | — | |
| SCHEMBL24732011 | 0.61 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL7772376 | 0.61 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, RYR2 | CHRNB2 408/4885CHRNA4 946/4885CHRNA3 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.